title: Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program.
abstract: To reliably estimate the prognoses of patients with hepatocellular carcinoma (HCC), both liver function and tumor-related factors should be accounted for. However, there are few worldwide staging systems that assess prognostic value in the context of selecting individual patients for randomized stratification in therapeutic and clinical trials. We investigated the value of known prognostic systems and verified the usefulness of the new scoring system proposed by the Cancer of the Liver Italian Program (CLIP), as determined from 662 Japanese patients. A retrospective analysis of the HCC diagnoses at 4 Japanese institutions from 1990 and 1998 was performed. Overall survival was the only end point used in the analysis. Discriminatory ability and predictive power of the CLIP score were compared with those of Okuda stage and AJCC TNM stage. Compared with the Okuda and AJCC staging systems, the CLIP score's enhanced discriminatory capacity, which was tested by the linear trend test and Harrels' c-index, revealed a class of patients with an impressively more favorable prognosis and another class with a relatively shorter life expectancy. Moreover, the likelihood ratio test showed that the CLIP score had additional homogeneity of survival within each score above that of the Okuda stage or the AJCC stage. This was true for 3 subgroups of patients who received surgery, transcatheter arterial chemoembolizations, and percutaneous ethanol injections. Collectively, these findings indicate that the CLIP score has the highest stratification ability with regard to prognosis in patients with HCC. The CLIP score could be used internationally to stratify randomization groups in therapeutic and clinical trials.
authors.affiliation: First Department of Surgery, Kagoshima University, School of Medicine, Kagoshima, Japan. ueno1@m.kufm.kagoshima-u.ac.jp
authors.forename: S
authors.initials: S
authors.lastname: Ueno
authors.forename: G
authors.initials: G
authors.lastname: Tanabe
authors.forename: K
authors.initials: K
authors.lastname: Sako
authors.forename: T
authors.initials: T
authors.lastname: Hiwaki
authors.forename: H
authors.initials: H
authors.lastname: Hokotate
authors.forename: Y
authors.initials: Y
authors.lastname: Fukukura
authors.forename: Y
authors.initials: Y
authors.lastname: Baba
authors.forename: Y
authors.initials: Y
authors.lastname: Imamura
authors.forename: T
authors.initials: T
authors.lastname: Aikou
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D016002:Discriminant Analysis; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D008297:Male; D008722:Methods; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis